Silence Therapeutics
SLN
6 hedge funds and large institutions have $55.9M invested in Silence Therapeutics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
448% more capital invested
Capital invested by funds: $10.2M → $55.9M (+$45.7M)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more funds holding
Funds holding: 3 → 6 (+3)
2.2% more ownership
Funds ownership: 0.65% → 2.85% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$16.2M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$16M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.8M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$5.41M |
| 5 |
Morgan Stanley
New York
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LOAMU
1
Lombard Odier Asset Management (USA)
New York
| $24.4M | +$16M | +658,141 | +122% |
|
|
BI
2
BVF Inc
San Francisco,
California
| $15.8M | +$16.2M | +666,666 | New |
|
|
3
Adage Capital Partners
Boston,
Massachusetts
| $10.2M | +$10.8M | +444,444 | New |
|
|
CCM
4
Consonance Capital Management
New York
| $5.11M | +$5.41M | +222,222 | New |
|
|
5
Morgan Stanley
New York
| $233K | +$197K | +8,118 | +406% |
|
6
SG Americas Securities
New York
| $129K | +$132K | +5,445 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$2K | -93 | Closed |
|
SLN Hedge Fund Activity: Q1 2021 in Review
6 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2021, worth a combined $55.9M — up 448% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SLN positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $16.2M. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 6 institutional investors held Silence Therapeutics (SLN) as of Q1 2021, up from 3 in Q4 2020.
- Funds reported $55.9M of Silence Therapeutics stock for Q1 2021, up 448% quarter-over-quarter.
- 4 funds opened new Silence Therapeutics positions in Q1 2021 and 1 closed out, a net change of +3 holders.
- The largest Silence Therapeutics buyer in Q1 2021 was BVF Inc, an estimated $16.2M added.
- The largest Silence Therapeutics seller in Q1 2021 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q1 2021.